NCT05718570
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Enrolling by Invitation
Not specifiedAges 18+ObservationalNovo Nordisk A/S
~400 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Somapacitan
At a glance
Recruiting sites
0 of 55 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Adverse drug reaction (ADRs)
Measured over From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
+2 more outcomes measured
Conditions
Where it's being run
55 sites across 22 statesGermany10
Japan6
France5
California4
Texas4
Saudi Arabia4
Massachusetts3
Nevada2
Study leadership
- Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of Adverse drug reaction (ADRs)From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as count of events.
- Incident NeoplasmFrom baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as number of participants (yes/no).
- Incident Diabetes Mellitus type 2From baseline (week 0) to end of study (between 1 week and a maximum of 10 years)
Measured as number of participants (yes/no).